The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single‐centre real‐life experience
Introduction This analysis attempts to determine the diagnostic and prognostic value of bone marrow (BM) evaluation by multiparameter flow cytometry in patients with myelodysplastic syndrome (MDS). Materials and methods The study group consisted of patients who underwent diagnostic process in the ye...
Gespeichert in:
| Veröffentlicht in: | Scandinavian journal of immunology 2021-08, Vol.94 (2), p.e13028-n/a |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 2 |
| container_start_page | e13028 |
| container_title | Scandinavian journal of immunology |
| container_volume | 94 |
| creator | Majcherek, Maciej Kiernicka‐Parulska, Jolanta Mierzwa, Anna Barańska, Marta Matuszak, Magdalena Lewandowski, Krzysztof Komarnicki, Mieczysław Czyż, Anna |
| description | Introduction
This analysis attempts to determine the diagnostic and prognostic value of bone marrow (BM) evaluation by multiparameter flow cytometry in patients with myelodysplastic syndrome (MDS).
Materials and methods
The study group consisted of patients who underwent diagnostic process in the years 2008‐2017 due to cytopenia and finally were diagnosed with MDS (n = 71). The comparative group included patients with cytopenia diagnosed in the same period, whose definitive diagnosis was other than MDS (n = 39). Flow cytometric evaluation of BM was performed following the recommendations of the European LeukemiaNet (ELN) in all patients.
Results
The median number of immunophenotypic abnormalities found on granulocytes in the MDS group was significantly higher compared to the comparative group [2 (range 0‐5) vs 0 (range 0‐2); P |
| doi_str_mv | 10.1111/sji.13028 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2489246981</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2552119886</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3888-53ed64b4046801a7ca4418f7685bbe3a75aeed22a8c4ede580688386581874783</originalsourceid><addsrcrecordid>eNp1kUFu1TAQQC0Eop_CggsgS2xgkdaO7dh_iapCi75gQVlHjj35-OPYwU5UsuMIXI0rcJK6pGWBhDfW2G_ejGYQek7JCS3nNB_cCWWkVg_QhrJGVIwo9hBtCCOk2nIpjtCTnA-EUFZL9hgdMSakpExu0K-rL4Ct0_sQ8-QM1sHiMcX7MLt9cL0zOhjAsce9j9fYLFMcYErlv4sB8KBTKs86Z8h5gDBhF_CwgI92yaPXq2kJNpW0jLUxMVkX9niKeCrlz-cUR9AB72D-CoPTH2DCCUwciszqycWQb5W55Hj4_eOnKTUSFET7EnnXA4bvIyQHpc2n6FGvfYZnd_cx-vz2_Orsotp9fHd59mZXGaaUqgQD2_COE94oQrU0mnOqetko0XXAtBQawNa1VoaDBaFIoxRTjVBUSS4VO0avVm8Z17cZ8tQOLhvwXgeIc25rrrY1b7aKFvTlP-ghzimU7tpaiJrSrVJNoV6vlEkx5wR9OyZXZru0lLS3e27Lnts_ey7sizvj3A1g_5L3iy3A6QpcOw_L_03tp_eXq_IGpda5WA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2552119886</pqid></control><display><type>article</type><title>The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single‐centre real‐life experience</title><source>Wiley Online Library</source><source>Wiley Online Library Free Content</source><source>EZB Electronic Journals Library</source><creator>Majcherek, Maciej ; Kiernicka‐Parulska, Jolanta ; Mierzwa, Anna ; Barańska, Marta ; Matuszak, Magdalena ; Lewandowski, Krzysztof ; Komarnicki, Mieczysław ; Czyż, Anna</creator><creatorcontrib>Majcherek, Maciej ; Kiernicka‐Parulska, Jolanta ; Mierzwa, Anna ; Barańska, Marta ; Matuszak, Magdalena ; Lewandowski, Krzysztof ; Komarnicki, Mieczysław ; Czyż, Anna</creatorcontrib><description>Introduction
This analysis attempts to determine the diagnostic and prognostic value of bone marrow (BM) evaluation by multiparameter flow cytometry in patients with myelodysplastic syndrome (MDS).
Materials and methods
The study group consisted of patients who underwent diagnostic process in the years 2008‐2017 due to cytopenia and finally were diagnosed with MDS (n = 71). The comparative group included patients with cytopenia diagnosed in the same period, whose definitive diagnosis was other than MDS (n = 39). Flow cytometric evaluation of BM was performed following the recommendations of the European LeukemiaNet (ELN) in all patients.
Results
The median number of immunophenotypic abnormalities found on granulocytes in the MDS group was significantly higher compared to the comparative group [2 (range 0‐5) vs 0 (range 0‐2); P < .0001]. Similarly, the median Ogata score was significantly higher in the MDS group [2 (range 0‐4) vs 1 (range 0‐3); P < .0001]. Since the disturbances of the CD11b/HLA‐DR and CD11b/CD13 on granulocytes were significantly more common in MDS patients, the Ogata score was extended by these abnormalities, what resulted in its higher diagnostic sensitivity (82%) while preserving high specificity (87%). The positive correlation was found between risk score determined by the Revised International Prognostic Scoring System and the number of the BM immunophenotypic abnormalities (P = .017).
Conclusions
Our results indicate that the diagnostic usefulness of the Ogata score may be increased by including the abnormal expression of CD11b/HLA‐DR and CD11b/CD13 on granulocytes. Moreover, our findings suggest the prognostic significance of the number of BM cytometric abnormalities in MDS.</description><identifier>ISSN: 0300-9475</identifier><identifier>EISSN: 1365-3083</identifier><identifier>DOI: 10.1111/sji.13028</identifier><identifier>PMID: 33577137</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Bone marrow ; CD11b antigen ; CD13 antigen ; Flow cytometry ; Granulocytes ; Histocompatibility antigen HLA ; Leukocytes (granulocytic) ; Medical diagnosis ; Myelodysplastic syndrome ; Myelodysplastic syndromes</subject><ispartof>Scandinavian journal of immunology, 2021-08, Vol.94 (2), p.e13028-n/a</ispartof><rights>2021 The Scandinavian Foundation for Immunology</rights><rights>2021 The Scandinavian Foundation for Immunology.</rights><rights>Copyright © 2021 The Scandinavian Foundation for Immunology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3888-53ed64b4046801a7ca4418f7685bbe3a75aeed22a8c4ede580688386581874783</citedby><cites>FETCH-LOGICAL-c3888-53ed64b4046801a7ca4418f7685bbe3a75aeed22a8c4ede580688386581874783</cites><orcidid>0000-0001-6641-0182 ; 0000-0001-6064-296X ; 0000-0003-0992-2020</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fsji.13028$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fsji.13028$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,1432,27915,27916,45565,45566,46400,46824</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33577137$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Majcherek, Maciej</creatorcontrib><creatorcontrib>Kiernicka‐Parulska, Jolanta</creatorcontrib><creatorcontrib>Mierzwa, Anna</creatorcontrib><creatorcontrib>Barańska, Marta</creatorcontrib><creatorcontrib>Matuszak, Magdalena</creatorcontrib><creatorcontrib>Lewandowski, Krzysztof</creatorcontrib><creatorcontrib>Komarnicki, Mieczysław</creatorcontrib><creatorcontrib>Czyż, Anna</creatorcontrib><title>The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single‐centre real‐life experience</title><title>Scandinavian journal of immunology</title><addtitle>Scand J Immunol</addtitle><description>Introduction
This analysis attempts to determine the diagnostic and prognostic value of bone marrow (BM) evaluation by multiparameter flow cytometry in patients with myelodysplastic syndrome (MDS).
Materials and methods
The study group consisted of patients who underwent diagnostic process in the years 2008‐2017 due to cytopenia and finally were diagnosed with MDS (n = 71). The comparative group included patients with cytopenia diagnosed in the same period, whose definitive diagnosis was other than MDS (n = 39). Flow cytometric evaluation of BM was performed following the recommendations of the European LeukemiaNet (ELN) in all patients.
Results
The median number of immunophenotypic abnormalities found on granulocytes in the MDS group was significantly higher compared to the comparative group [2 (range 0‐5) vs 0 (range 0‐2); P < .0001]. Similarly, the median Ogata score was significantly higher in the MDS group [2 (range 0‐4) vs 1 (range 0‐3); P < .0001]. Since the disturbances of the CD11b/HLA‐DR and CD11b/CD13 on granulocytes were significantly more common in MDS patients, the Ogata score was extended by these abnormalities, what resulted in its higher diagnostic sensitivity (82%) while preserving high specificity (87%). The positive correlation was found between risk score determined by the Revised International Prognostic Scoring System and the number of the BM immunophenotypic abnormalities (P = .017).
Conclusions
Our results indicate that the diagnostic usefulness of the Ogata score may be increased by including the abnormal expression of CD11b/HLA‐DR and CD11b/CD13 on granulocytes. Moreover, our findings suggest the prognostic significance of the number of BM cytometric abnormalities in MDS.</description><subject>Bone marrow</subject><subject>CD11b antigen</subject><subject>CD13 antigen</subject><subject>Flow cytometry</subject><subject>Granulocytes</subject><subject>Histocompatibility antigen HLA</subject><subject>Leukocytes (granulocytic)</subject><subject>Medical diagnosis</subject><subject>Myelodysplastic syndrome</subject><subject>Myelodysplastic syndromes</subject><issn>0300-9475</issn><issn>1365-3083</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp1kUFu1TAQQC0Eop_CggsgS2xgkdaO7dh_iapCi75gQVlHjj35-OPYwU5UsuMIXI0rcJK6pGWBhDfW2G_ejGYQek7JCS3nNB_cCWWkVg_QhrJGVIwo9hBtCCOk2nIpjtCTnA-EUFZL9hgdMSakpExu0K-rL4Ct0_sQ8-QM1sHiMcX7MLt9cL0zOhjAsce9j9fYLFMcYErlv4sB8KBTKs86Z8h5gDBhF_CwgI92yaPXq2kJNpW0jLUxMVkX9niKeCrlz-cUR9AB72D-CoPTH2DCCUwciszqycWQb5W55Hj4_eOnKTUSFET7EnnXA4bvIyQHpc2n6FGvfYZnd_cx-vz2_Orsotp9fHd59mZXGaaUqgQD2_COE94oQrU0mnOqetko0XXAtBQawNa1VoaDBaFIoxRTjVBUSS4VO0avVm8Z17cZ8tQOLhvwXgeIc25rrrY1b7aKFvTlP-ghzimU7tpaiJrSrVJNoV6vlEkx5wR9OyZXZru0lLS3e27Lnts_ey7sizvj3A1g_5L3iy3A6QpcOw_L_03tp_eXq_IGpda5WA</recordid><startdate>202108</startdate><enddate>202108</enddate><creator>Majcherek, Maciej</creator><creator>Kiernicka‐Parulska, Jolanta</creator><creator>Mierzwa, Anna</creator><creator>Barańska, Marta</creator><creator>Matuszak, Magdalena</creator><creator>Lewandowski, Krzysztof</creator><creator>Komarnicki, Mieczysław</creator><creator>Czyż, Anna</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>8FD</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6641-0182</orcidid><orcidid>https://orcid.org/0000-0001-6064-296X</orcidid><orcidid>https://orcid.org/0000-0003-0992-2020</orcidid></search><sort><creationdate>202108</creationdate><title>The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single‐centre real‐life experience</title><author>Majcherek, Maciej ; Kiernicka‐Parulska, Jolanta ; Mierzwa, Anna ; Barańska, Marta ; Matuszak, Magdalena ; Lewandowski, Krzysztof ; Komarnicki, Mieczysław ; Czyż, Anna</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3888-53ed64b4046801a7ca4418f7685bbe3a75aeed22a8c4ede580688386581874783</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Bone marrow</topic><topic>CD11b antigen</topic><topic>CD13 antigen</topic><topic>Flow cytometry</topic><topic>Granulocytes</topic><topic>Histocompatibility antigen HLA</topic><topic>Leukocytes (granulocytic)</topic><topic>Medical diagnosis</topic><topic>Myelodysplastic syndrome</topic><topic>Myelodysplastic syndromes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Majcherek, Maciej</creatorcontrib><creatorcontrib>Kiernicka‐Parulska, Jolanta</creatorcontrib><creatorcontrib>Mierzwa, Anna</creatorcontrib><creatorcontrib>Barańska, Marta</creatorcontrib><creatorcontrib>Matuszak, Magdalena</creatorcontrib><creatorcontrib>Lewandowski, Krzysztof</creatorcontrib><creatorcontrib>Komarnicki, Mieczysław</creatorcontrib><creatorcontrib>Czyż, Anna</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Scandinavian journal of immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Majcherek, Maciej</au><au>Kiernicka‐Parulska, Jolanta</au><au>Mierzwa, Anna</au><au>Barańska, Marta</au><au>Matuszak, Magdalena</au><au>Lewandowski, Krzysztof</au><au>Komarnicki, Mieczysław</au><au>Czyż, Anna</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single‐centre real‐life experience</atitle><jtitle>Scandinavian journal of immunology</jtitle><addtitle>Scand J Immunol</addtitle><date>2021-08</date><risdate>2021</risdate><volume>94</volume><issue>2</issue><spage>e13028</spage><epage>n/a</epage><pages>e13028-n/a</pages><issn>0300-9475</issn><eissn>1365-3083</eissn><abstract>Introduction
This analysis attempts to determine the diagnostic and prognostic value of bone marrow (BM) evaluation by multiparameter flow cytometry in patients with myelodysplastic syndrome (MDS).
Materials and methods
The study group consisted of patients who underwent diagnostic process in the years 2008‐2017 due to cytopenia and finally were diagnosed with MDS (n = 71). The comparative group included patients with cytopenia diagnosed in the same period, whose definitive diagnosis was other than MDS (n = 39). Flow cytometric evaluation of BM was performed following the recommendations of the European LeukemiaNet (ELN) in all patients.
Results
The median number of immunophenotypic abnormalities found on granulocytes in the MDS group was significantly higher compared to the comparative group [2 (range 0‐5) vs 0 (range 0‐2); P < .0001]. Similarly, the median Ogata score was significantly higher in the MDS group [2 (range 0‐4) vs 1 (range 0‐3); P < .0001]. Since the disturbances of the CD11b/HLA‐DR and CD11b/CD13 on granulocytes were significantly more common in MDS patients, the Ogata score was extended by these abnormalities, what resulted in its higher diagnostic sensitivity (82%) while preserving high specificity (87%). The positive correlation was found between risk score determined by the Revised International Prognostic Scoring System and the number of the BM immunophenotypic abnormalities (P = .017).
Conclusions
Our results indicate that the diagnostic usefulness of the Ogata score may be increased by including the abnormal expression of CD11b/HLA‐DR and CD11b/CD13 on granulocytes. Moreover, our findings suggest the prognostic significance of the number of BM cytometric abnormalities in MDS.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>33577137</pmid><doi>10.1111/sji.13028</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-6641-0182</orcidid><orcidid>https://orcid.org/0000-0001-6064-296X</orcidid><orcidid>https://orcid.org/0000-0003-0992-2020</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0300-9475 |
| ispartof | Scandinavian journal of immunology, 2021-08, Vol.94 (2), p.e13028-n/a |
| issn | 0300-9475 1365-3083 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2489246981 |
| source | Wiley Online Library; Wiley Online Library Free Content; EZB Electronic Journals Library |
| subjects | Bone marrow CD11b antigen CD13 antigen Flow cytometry Granulocytes Histocompatibility antigen HLA Leukocytes (granulocytic) Medical diagnosis Myelodysplastic syndrome Myelodysplastic syndromes |
| title | The diagnostic and prognostic significance of flow cytometric bone marrow assessment in myelodysplastic syndromes according to the European LeukemiaNet recommendations in single‐centre real‐life experience |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T18%3A47%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20diagnostic%20and%20prognostic%20significance%20of%20flow%20cytometric%20bone%20marrow%20assessment%20in%20myelodysplastic%20syndromes%20according%20to%20the%20European%20LeukemiaNet%20recommendations%20in%20single%E2%80%90centre%20real%E2%80%90life%20experience&rft.jtitle=Scandinavian%20journal%20of%20immunology&rft.au=Majcherek,%20Maciej&rft.date=2021-08&rft.volume=94&rft.issue=2&rft.spage=e13028&rft.epage=n/a&rft.pages=e13028-n/a&rft.issn=0300-9475&rft.eissn=1365-3083&rft_id=info:doi/10.1111/sji.13028&rft_dat=%3Cproquest_cross%3E2552119886%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2552119886&rft_id=info:pmid/33577137&rfr_iscdi=true |